Ethema Health Corp (GRST)

[Bubae]

History matters.

It would be instructive to look at the decline to .0001 in January 2020. December 24, 2019 the company begins promoting a new letter of intent to acquire a company with approximately $20 million in revenue for 2019 and an EBITDA of $3.6 Million. This LOI was later let to expire without action. The company raises the authorized share count from 900 million to 10 billion shares in an 8K releases January 6th 2020. LABRYS fund note of July 2019 becomes eligible on January 11th 2020. The price drops from that point to the end of February 2020 to .0001 and stays there for four months. January 2020 began with only 155 million shares outstanding, trading around .0025.

Now with nearly 3.6 billion shares outstanding LABRYS fund is currently holding two notes totaling $780K that are eligible to convert.





First day of trading January 2020 was the 2nd and the price closed at .0029

January 10th date before note maturity price closed at .0023.

The first trade at .0001 occurred around the 5th of February 2020.

8K filing Date of Report (Date of earliest event reported): July 19, 2019

https://sec.report/Document/0001721868-19-000351/

item 1.01 Entry into a Material Definitive Agreement.

On July 15, 2019, Ethema Health Corporation, a Colorado corporation, f/k/a/ GreeneStone Healthcare Corporation (the “Company”) closed on a private offering (the “Private Offering”) to raise USD$282,000.00 in capital. Pursuant to the Private Offering, the Company issued one convertible promissory note (the "Note"), bearing a principal amount of USD$282,000.00 in total, to Labrys Fund LLC (the “Investor”).

Unless otherwise provided for in the Note, the Note bears a 10% interest rate and matures 180 days from the date of issuance, on January 11, 2020 (the “Maturity Date”). The Investor has conversion rights under the Note, from time to time and at any time after 180 days from the Note issuance date, to convert all or any part of the outstanding and unpaid principal amount of the Note into fully paid and non-assessable shares of the Company’s common stock,
1.2 Conversion Price.

(a) Calculation of Conversion Price. Subject to the adjustments described herein, the conversion price (the “Conversion Price”) shall equal the lesser of (i) 60% multiplied by the lowest Trading Price (as defined below) (representing a discount rate of 40%) during the previous thirty (30) Trading Day period ending on the latest complete Trading Day prior to the date of this Note and (ii) the Alternate Conversion Price (as defined herein)(subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower’s securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The “Alternate Conversion Price” shall mean 60% multiplied by the Market Price (as defined herein) (representing a discount rate of 40%). “Market Price” means the lowest Trading Price (as defined below) for the Common Stock during the thirty (30) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.

8K filing for increase in authorized shares.

Date of Report (Date of earliest event reported): January 6, 2020
https://sec.report/Document/0001721868-20-000036/

On January 6, 2020, a majority of the holders of the issued and outstanding shares of common stock of Ethema Health Corporation (the “Company”) approved the increase of its authorized aggregate number of shares of common stock issuable from nine hundred million (900,000,000) to ten billion (10,000,000,000), as a result the Company’s current authorized capital



For the quarterly period ended March 31, 2020
https://sec.report/Document/0001721868-20-000426/

Authorized, issued and outstanding

The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued and outstanding common shares of 1,577,862,975 and 155,483,897 as of March 31, 2020 and December 31, 2019, respectively.

Between January 6, 2020 and February 27, 2020, the Company issued 1,316,679,078 shares of common stock in terms of conversion notices received from convertible note holders. The shares issued were issued below par based on the market price of the stock on the date of conversion and were valued at $531,005.